Idorsia QUVIVIQ sales jump 62% as daridorexant pipeline broadens
Idorsia has reported first-half 2026 net sales of CHF 91 million for its insomnia treatment QUVIVIQ (daridorexant), a 62% increase on the CHF 56 million posted in the same period of 2025. The Swiss biopharmaceutical company, listed on the SIX Swiss Exchange, reaffirmed its full-year 2026 QUVIVIQ sales guidance of CHF 200 million and outlined four strategic growth drivers it intends to pursue over the coming months.
The headline commercial figure is encouraging, but the broader financial picture is more mixed. US GAAP net loss for the half widened to CHF 153 million from CHF 52 million net income a year ago, primarily driven by CHF 81 million in additional financial expenses including a CHF 47 million non-cash debt extinguishment charge. Non-GAAP operating loss stood at CHF 54 million. Total indebtedness reached CHF 1.4 billion at 30 June 2026, though Idorsia notes that debt notes in its special-purpose vehicle account for CHF 766 million of that total.
Commercial and clinical expansion
Idorsia is pursuing a multi-axis expansion of QUVIVIQ. On geography, the company has secured public reimbursement in France, Germany, the United Kingdom, and Austria, and is advancing discussions in Spain, Canada, and the Nordic region. A new co-promotion agreement with Viatris covering Italy and Canada adds to existing partnerships with the Menarini Group across four European markets. A direct-to-patient access model is also being prepared for several geographies.
Beyond insomnia in adults, a Phase 2 study of daridorexant in paediatric insomnia generated results described as showing a statistically significant, dose-dependent increase in total sleep time with a favourable tolerability profile. Regulatory discussions are under way to define a pathway toward a dedicated paediatric indication. The company is also designing a programme targeting a neurodevelopmental disorder beyond insomnia, citing encouraging signals observed in the paediatric study.
The US label-enabling study on daytime functioning is expected to start within weeks, and a separate process to remove scheduling restrictions for the dual orexin receptor antagonist class continues at the FDA. Removing schedule status would be a material commercial event, potentially broadening prescriber access in primary care.
Pipeline and leadership
Beyond daridorexant, Idorsia's second approved product, the dual endothelin receptor antagonist TRYVIO/JERAYGO (aprocitentan) for difficult-to-control hypertension, is being commercialised via a special-purpose vehicle structure. The SPV has received an offer of third-party financing to fund co-promotion partnerships in the US and Europe, a capital-efficient model that, the company says, removes financial risk for Idorsia itself.
Further pipeline milestones include: initiation of a pivotal lucerastat kidney biopsy study in Fabry disease in Q3 2026; results from a CCR6 receptor antagonist proof-of-concept study in psoriasis expected in Q4 2026; and a novel CFTR Type-IV corrector for cystic fibrosis targeting Phase 1 entry before year-end.
Roland Wandeler is set to assume the chief executive role on 1 October 2026, succeeding Jean-Paul Clozel who has been serving as interim CEO. Arno Groenewoud, chief financial officer, said the company had "significantly strengthened our financial position by securing additional non-dilutive financing and eliminating our near-term debt maturities."
The dual orexin receptor antagonist market has become increasingly competitive since the approval of Merck's suvorexant and, more recently, Eisai's lemborexant. Daridorexant's differentiation rests partly on its shorter half-life and the daytime-functioning data Idorsia is generating. Whether expanded paediatric and neurodevelopmental indications can materially move revenues will depend on regulatory timelines and the pace of prescriber adoption in primary care, where DORA class penetration remains limited relative to the overall sleep disorder market.